High-dose ranitidine for the prevention of recurrent peptic ulcer disease in rheumatoid arthritis patients taking NSAIDs

Alimentary Pharmacology and Therapeutics

Volumn 10, Issue 3, 1996, Pages 347-351

  Ten Wolde, S ^a   Dijkmans, B A C ^a   Janssen, M ^a   Hermans, J ^a   Lamers, C B H W ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RANITIDINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DUODENUM ULCER; FEMALE; HUMAN; MALE; PEPTIC ULCER; PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RHEUMATOID ARTHRITIS; SIDE EFFECT; STOMACH ULCER;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; FEMALE; GASTROSCOPY; HUMANS; MALE; MIDDLE AGED; PEPTIC ULCER; RANITIDINE; RECURRENCE;

EID: 0030013656     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0953-0673.1996.00347.x     Document Type: Article

References (27)

1. Soll AH. Pathogenesis of peptic ulcer and implications for therapy. N Engl J Med 1990; 322:909-16.
2. Schubert TT, Bologna SD, Nensey Y, et al. Ulcer risk factors: interactions between Helicobacter pylori infection, nonsteroidal use, and age. Am J Med 1993; 94: 413-8.
3. Janssen M, Dijkmans BAC, Lamers CBHW, Zwinderman AH, Vandenbroucke JP. A gastroscopic study of the predictive value of risk factors for non-steroidal anti-inflammatory drug-associated ulcer disease in rheumatoid arthritis patients. Br J Rheum 1994; 33: 449-54.
4. Hentschel E, Brandstätter G, Dragosics B, et al. Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med 1993; 328: 308-12.
5. Van Deventer GM, Elashoff JD, Reedy TJ, Schneidman D, Walsh JH. A randomized study of maintenance therapy with ranitidine to prevent the recurrence of duodenal ulcer. N Engl J Med 1989; 320: 1113-9.
6. Jensen DM, Cheng S, Kovacs TOG, et al. A controlled study of ranitidine for the prevention of recurrent hemorrhage from duodenal ulcer. N Engl J Med 1994; 330: 382-6.
7. 2-receptor antagonists. Aliment Pharmacol Ther 1993; 7: 27-33.
8. Ensanullah RSB, Page MC, Tildesley G, Wood JR. Prevention of gastroduodenal damage induced by non-steroidal antiinflammatory drugs: controlled trial of ranitidine. BMJ 1988; 297: 1017-21.
9. Raskin J, White R, Jaszewski R. Double-blind comparitive study of the efficacy and safety of misoprostol and ranitidine in the prevention of NSAID-induced gastric ulcers and upper GI symptoms: preliminary findings. Digestion 1991; 49 (Suppl. 1): 50-1.
10. Lanza FL, Aspinall RL, Swabb EA, et al. Double-blind, placebo-controlled endoscopie comparison of the mucosal protective effects of misoprostol versus cimetidine on tolmetin-induced mucosal injury to the stomach and duodenum. Gastroenterology 1988; 95: 289-94.
11. Wormsley KG. Safety profile of ranitidine - a review. Drugs 1993; 46: 976-85.
12. Farah D, Shurrock RD, Russel RI. Peptic ulcer in rheumatoid arthritis. Ann Rheum Dis 1988; 47: 478-80.
13. García Rodríguez LA, Jick H. Risk of upper gastro-intestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 769-72.
14. Arnett FC, Edworthy SM, Block DA. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
15. Steinbrocker O, Treager CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. JAMA 1949; 140: 659-62.
16. Siegert CEH, Vleming L-J, Vandenbroucke JP, Cats A. Measurement of disability in Dutch rheumatoid arthritis patients. Clin Rheumatol 1984; 3: 305-9.
17. Pena AS, Endts HPh, Offerhaus GJA, et al. Value of serology (ELISA and immunoblotting) for the diagnosis of Campylobacter pylori infection. Digestion 1989; 44: 131-41.
18. Desforges JF. Helicobacter pylori and peptic ulcer disease. N Engl J Med 1991; 324: 1043-8.
19. Hendriksson K, Uribe A, Sandstedt B, Nord CE. Helicobacter pylori infection. ABO blood group, and effect of misoprostol on gastroduodenal mucosa in NSAID-treated patients with rheumatoid arthritis. Dig Dis Sci 1993; 38: 1688-96.
20. Ballinger AB, Kumar PJ, Scott DL. Misoprostol in the prevention of gastroduodenal damage in rheumatology. Ann Rheum Dis 1992; 51: 1089-93.
21. Graham DY, White RH, Moreland LW, et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Ann Intern Med 1993; 119: 257-62.
22. Redfern JS, Feldman M. Role of endogenous prostaglandins in preventing gastrointestinal ulceration: induction of ulcers by antibodies to prostaglandins. Gastroenterology 1989; 96 (Suppl.): 596-605.
23. Dammann HG, Walter TA. Efficacy of continuous therapy for peptic ulcer in controlled clinical trials. Aliment Pharmacol Ther 1993; 46: 976-85.
24. 2-receptor antagonists. Aliment Pharmacol Ther 1993; 7: 35-40.
25. Arnold R. Safety of proton pump inhibitors - an overview. Aliment Pharmacol Ther 1994; 8: 65-70.
26. Mellem H, Stave R, Myren J, et al. Symptoms in patients with peptic ulcer and hematesis and/or melena related to the use of non-steroidal anti-inflammatory drugs. Scand J Gastroenterol 1985; 20: 1246-8.
27. Janssen M, Dijkmans BAC, van der Sluijs FA, et al. Upper gastro-intestinal complaints and complications in chronic rheumatic patients in comparison with other chronic diseases. Br J Rheum 1992; 31: 747-52.